Division of Nephrology, Department of Medicine, Icahn School of Medicine at Mount Sinai, One Gustave L Levy Place, Box 1243, New York, NY, 10029, USA.
Division of Gastroenterology and Nutrition, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
Hepatol Int. 2016 May;10(3):525-31. doi: 10.1007/s12072-016-9706-9. Epub 2016 Jan 29.
Cirrhosis affects 5.5 million patients with estimated costs of US$4 billion. Previous studies about dialysis requiring acute kidney injury (AKI-D) in decompensated cirrhosis (DC) are from a single center/year. We aimed to describe national trends of incidence and impact of AKI-D in DC hospitalizations.
We extracted our cohort from the Nationwide Inpatient Sample (NIS) from 2006-2012. We identified hospitalizations with DC and AKI-D by validated ICD9 codes. We analyzed temporal changes in DC hospitalizations complicated by AKI-D and utilized multivariable logistic regression models to estimate AKI-D impact on hospital mortality.
We identified a total of 3,655,700 adult DC hospitalizations from 2006 to 2012 of which 78,015 (2.1 %) had AKI-D. The proportion with AKI-D increased from 1.5 % in 2006 to 2.23 % in 2012; it was stable between 2009 and 2012 despite an increase in absolute numbers from 6773 to 13,930. The overall hospital mortality was significantly higher in hospitalizations with AKI-D versus those without (40.87 vs. 6.96 %; p < 0.001). In an adjusted multivariable analysis, adjusted odds ratio for mortality was 2.17 (95 % CI 2.06-2.28; p < 0.01) with AKI-D, which was stable from 2006 to 2012. Changes in demographics and increases in acute/chronic comorbidities and procedures explained temporal changes in AKI-D.
Proportion of DC hospitalizations with AKI-D increased from 2006 to 2009, and although this was stable from 2009 to 2012, there was an increase in absolute cases. These results elucidate the burden of AKI-D on DC hospitalizations and excess associated mortality, as well as highlight the importance of prevention, early diagnosis and testing of novel interventions in this vulnerable population.
肝硬化影响着 550 万患者,其估计费用为 40 亿美元。以前关于失代偿性肝硬化(DC)中需要急性肾损伤(AKI-D)透析的研究均来自单一中心/年。我们旨在描述全国范围内 DC 住院患者 AKI-D 的发病率和影响的趋势。
我们从 2006 年至 2012 年的全国住院患者样本(NIS)中提取了我们的队列。我们通过验证的 ICD9 代码确定了伴有 DC 和 AKI-D 的住院病例。我们分析了 AKI-D 并发 DC 住院的时间变化,并利用多变量逻辑回归模型来估计 AKI-D 对医院死亡率的影响。
我们从 2006 年至 2012 年共确定了 3655700 例成年 DC 住院患者,其中 78015 例(2.1%)患有 AKI-D。AKI-D 的比例从 2006 年的 1.5%增加到 2012 年的 2.23%;尽管绝对数字从 6773 例增加到 13930 例,但在 2009 年至 2012 年之间保持稳定。与无 AKI-D 的住院患者相比,AKI-D 住院患者的总体医院死亡率显著更高(40.87% vs. 6.96%;p<0.001)。在调整后的多变量分析中,AKI-D 调整后的死亡比值比为 2.17(95%CI 2.06-2.28;p<0.01),并且从 2006 年到 2012 年保持稳定。人口统计学的变化以及急性/慢性合并症和手术的增加解释了 AKI-D 的时间变化。
从 2006 年到 2009 年,伴有 AKI-D 的 DC 住院患者比例增加,尽管从 2009 年到 2012 年保持稳定,但绝对病例数有所增加。这些结果阐明了 AKI-D 对 DC 住院患者和相关超额死亡率的负担,以及在这一脆弱人群中强调预防、早期诊断和测试新干预措施的重要性。